Epidarex Capital is making waves again in the life sciences world.
The Edinburgh- and Bethesda-based venture firm recently held the first close of Epidarex Capital IV, LP, securing more than $145 million from its initial investors.
This milestone sets the stage for another chapter in the firm’s mission to nurture groundbreaking healthcare innovations across the UK and the US.
Diverse Investor Base Joins the Fund
The initial backing comes from a mix of influential public and private investors.
Key participants include the British Business Bank, Strathclyde Pension Fund, and the Scottish National Investment Bank, alongside family offices, corporates, and other international investors.
This broad support underscores confidence in Epidarex’s strategy and vision for early-stage healthcare ventures.
Targeting Cutting-Edge Healthcare Innovation
The Fund will focus on early-stage healthcare opportunities rooted in breakthrough science, giving researchers and entrepreneurs the chance to build companies from the ground up.
Areas of focus include oncology, cardiometabolic, autoimmune, and neurological conditions, addressing critical unmet medical needs.
By sourcing research from both established and emerging hubs in the UK and US, Epidarex aims to foster the next generation of healthcare leaders.
Building Companies Through Active Partnership
Led by Managing Partners Sinclair Dunlop and Elizabeth Roper, Epidarex takes a hands-on approach.
The team doesn’t just provide capital—they partner with scientists and entrepreneurs, helping to assemble high-performance leadership teams, shape company strategies, and navigate key value inflection points.
Their goal is to bridge the equity funding gap and build globally competitive companies from early-stage concepts.
Ambitious Investment Goals
Epidarex Capital IV, LP plans to invest in up to 15 companies, continuing the firm’s transatlantic growth story.
Its portfolio already includes notable names like Apellis Pharmaceuticals, Enterprise Therapeutics, Harpoon Medical, Kynos Therapeutics, and Nodthera, highlighting a track record of supporting innovative, high-impact ventures.
Looking Ahead
With the Fund’s first close completed, Epidarex is poised to identify and back the next wave of transformative healthcare companies.
For scientists and entrepreneurs, this represents a unique opportunity to turn pioneering research into companies that could redefine patient care across multiple disease areas.
Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn